{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T09:07:14Z","timestamp":1789895234899,"version":"4.0.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Program Management Unit for Competitiveness","award":["C10F640323"],"award-info":[{"award-number":["C10F640323"]}]},{"name":"The Program Management Unit for Competitiveness","award":["C10F640323"],"award-info":[{"award-number":["C10F640323"]}]},{"DOI":"10.13039\/501100004704","name":"The National Research Council of Thailand","doi-asserted-by":"crossref","award":["NRCT383\/2563"],"award-info":[{"award-number":["NRCT383\/2563"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nonalcoholic fatty liver disease (NAFLD) begins with benign steatosis caused by ectopic storage of triacylglycerols in the liver. Persistent steatosis, in combination with other genetic and environmental factors, leads to nonalcoholic steatohepatitis (NASH) characterized by functional impairment, inflammation, and fibrosis. However, it remains unclear how persistent steatosis directly contributes to the progression of NAFLD, which may represent a therapeutic target. The organ-on-a-chip (OOC) has emerged as a new culture platform to recapitulate human pathological conditions under which drug candidates can be screened. Here, we developed a simple OOC steatosis model using the Mimetas OrganoPlate with a human liver cell line, HepG2. Treating the HepG2 OOCs with fatty acid overload induced steatosis within 24\u00a0h. Moreover, persistent steatosis for 6\u00a0days impaired OOC viability and hepatic function, as measured by a WST-8 assay and albumin production, respectively. Lastly, the HepG2 OOCs were exposed to drugs being tested in clinical trials for NAFLD\/NASH during the 6-day period. Pioglitazone improved the OOC viability while elafibranor reduced the steatosis in association with reduced viability and albumin production. In conclusion, we show that the HepG2 steatosis OOC model is a useful tool on which the efficacy and toxicity of various therapeutic candidates can be tested.<\/jats:p>","DOI":"10.1038\/s41598-023-44198-0","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T16:01:56Z","timestamp":1696867316000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["A model of hepatic steatosis with declined viability and function in a liver-organ-on-a-chip"],"prefix":"10.1038","volume":"13","author":[{"given":"Natsupa","family":"Wiriyakulsit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ploychanok","family":"Keawsomnuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saowarose","family":"Thongin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pimonrat","family":"Ketsawatsomkron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Muta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"44198_CR1","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.3390\/ijms20205037","volume":"20","author":"DH Fernando","year":"2019","unstructured":"Fernando, D. H., Forbes, J. M., Angus, P. W. & Herath, C. B. Development and progression of non-alcoholic fatty liver disease: The role of advanced glycation end products. Int. J. Mol. Sci. 20, 5037. https:\/\/doi.org\/10.3390\/ijms20205037 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"44198_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","volume":"22","author":"S Pouwels","year":"2022","unstructured":"Pouwels, S. et al. Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss. BMC Endocr. Disord. 22, 63. https:\/\/doi.org\/10.1186\/s12902-022-00980-1 (2022).","journal-title":"BMC Endocr. Disord."},{"key":"44198_CR3","doi-asserted-by":"publisher","first-page":"603926","DOI":"10.3389\/fphar.2020.603926","volume":"11","author":"C Peng","year":"2020","unstructured":"Peng, C., Stewart, A. G., Woodman, O. L., Ritchie, R. H. & Qin, C. X. Non-Alcoholic steatohepatitis: A review of its mechanism, Models and Medical Treatments. Front. Pharmacol. 11, 603926. https:\/\/doi.org\/10.3389\/fphar.2020.603926 (2020).","journal-title":"Front. Pharmacol."},{"key":"44198_CR4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology 77, 1335\u20131347. https:\/\/doi.org\/10.1097\/HEP.0000000000000004 (2023).","journal-title":"Hepatology"},{"key":"44198_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jceh.2020.09.001","volume":"11","author":"D David","year":"2021","unstructured":"David, D. & Eapen, C. E. What are the current pharmacological therapies for nonalcoholic fatty liver disease?. J. Clin. Exp. Hepatol. 11, 232\u2013238. https:\/\/doi.org\/10.1016\/j.jceh.2020.09.001 (2021).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"44198_CR6","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.3390\/ijerph16224334","volume":"16","author":"G Pennisi","year":"2019","unstructured":"Pennisi, G. et al. Pharmacological therapy of non-alcoholic fatty liver disease: What drugs are available now and future perspectives. Int. J. Environ. Res. Public Health 16, 4334. https:\/\/doi.org\/10.3390\/ijerph16224334 (2019).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"44198_CR7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4103\/ijem.IJEM_585_17","volume":"22","author":"M Dharmalingam","year":"2018","unstructured":"Dharmalingam, M. & Yamasandhi, P. G. Nonalcoholic fatty liver disease and type 2 diabetes mellitus. Indian J. Endocrinol. Metab. 22, 421\u2013428. https:\/\/doi.org\/10.4103\/ijem.IJEM_585_17 (2018).","journal-title":"Indian J. Endocrinol. Metab."},{"key":"44198_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s13643-019-1200-8","volume":"8","author":"I Blazina","year":"2019","unstructured":"Blazina, I. & Selph, S. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. Syst. Rev. 8, 295. https:\/\/doi.org\/10.1186\/s13643-019-1200-8 (2019).","journal-title":"Syst. Rev."},{"key":"44198_CR9","doi-asserted-by":"publisher","first-page":"983814","DOI":"10.1155\/2012\/983814","volume":"2012","author":"M Snel","year":"2012","unstructured":"Snel, M. et al. Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. Int. J. Endocrinol. 2012, 983814. https:\/\/doi.org\/10.1155\/2012\/983814 (2012).","journal-title":"Int. J. Endocrinol."},{"key":"44198_CR10","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.jhep.2015.02.005","volume":"62","author":"LA Adams","year":"2015","unstructured":"Adams, L. A. & Ratziu, V. Non-alcoholic fatty liver-perhaps not so benign. J Hepatol 62, 1002\u20131004. https:\/\/doi.org\/10.1016\/j.jhep.2015.02.005 (2015).","journal-title":"J Hepatol"},{"key":"44198_CR11","doi-asserted-by":"publisher","first-page":"e26835","DOI":"10.1097\/MD.0000000000026835","volume":"100","author":"K Kawaguchi","year":"2021","unstructured":"Kawaguchi, K. et al. Decline in serum albumin concentration is a predictor of serious events in nonalcoholic fatty liver disease. Med. (Baltimore) 100, e26835. https:\/\/doi.org\/10.1097\/MD.0000000000026835 (2021).","journal-title":"Med. (Baltimore)"},{"key":"44198_CR12","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.3390\/nu9101072","volume":"9","author":"MA Van Herck","year":"2017","unstructured":"Van Herck, M. A., Vonghia, L. & Francque, S. M. Animal models of nonalcoholic fatty liver disease-A starter\u2019s guide. Nutrients 9, 1072. https:\/\/doi.org\/10.3390\/nu9101072 (2017).","journal-title":"Nutrients"},{"key":"44198_CR13","doi-asserted-by":"publisher","first-page":"103549","DOI":"10.1016\/j.isci.2021.103549","volume":"25","author":"MJ Ramos","year":"2022","unstructured":"Ramos, M. J., Bandiera, L., Menolascina, F. & Fallowfield, J. A. In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications. iScience 25, 103549. https:\/\/doi.org\/10.1016\/j.isci.2021.103549 (2022).","journal-title":"iScience"},{"key":"44198_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.taap.2014.02.001","volume":"276","author":"A Rogue","year":"2014","unstructured":"Rogue, A. et al. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. Toxicol. Appl. Pharmacol. 276, 73\u201381. https:\/\/doi.org\/10.1016\/j.taap.2014.02.001 (2014).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"44198_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12944-018-0762-0","volume":"17","author":"X Zhu","year":"2018","unstructured":"Zhu, X. et al. Metformin attenuates triglyceride accumulation in HepG2 cells through decreasing stearyl-coenzyme A desaturase 1 expression. Lipids Health Dis. 17, 114. https:\/\/doi.org\/10.1186\/s12944-018-0762-0 (2018).","journal-title":"Lipids Health Dis."},{"key":"44198_CR16","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1152\/physiol.00036.2016","volume":"32","author":"K Duval","year":"2017","unstructured":"Duval, K. et al. Modeling physiological events in 2D vs. 3D cell culture. Physiol. (Bethesda) 32, 266\u2013277. https:\/\/doi.org\/10.1152\/physiol.00036.2016 (2017).","journal-title":"Physiol. (Bethesda)"},{"key":"44198_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fphar.2018.00006","volume":"9","author":"SA Langhans","year":"2018","unstructured":"Langhans, S. A. Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front. Pharmacol. 9, 6. https:\/\/doi.org\/10.3389\/fphar.2018.00006 (2018).","journal-title":"Front. Pharmacol."},{"key":"44198_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12938-020-0752-0","volume":"19","author":"Q Wu","year":"2020","unstructured":"Wu, Q. et al. Organ-on-a-chip: Recent breakthroughs and future prospects. Biomed. Eng. Online 19, 9. https:\/\/doi.org\/10.1186\/s12938-020-0752-0 (2020).","journal-title":"Biomed. Eng. Online"},{"key":"44198_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/hep4.1647","volume":"5","author":"MS Freag","year":"2021","unstructured":"Freag, M. S. et al. Human nonalcoholic steatohepatitis on a chip. Hepatol. Commun. 5, 217\u2013233. https:\/\/doi.org\/10.1002\/hep4.1647 (2021).","journal-title":"Hepatol. Commun."},{"key":"44198_CR20","doi-asserted-by":"publisher","first-page":"13159","DOI":"10.1038\/s41598-021-92264-2","volume":"11","author":"VL Slaughter","year":"2021","unstructured":"Slaughter, V. L. et al. Validation of an adipose-liver human-on-a-chip model of NAFLD for preclinical therapeutic efficacy evaluation. Sci. Rep. 11, 13159. https:\/\/doi.org\/10.1038\/s41598-021-92264-2 (2021).","journal-title":"Sci. Rep."},{"key":"44198_CR21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/hep.31106","volume":"71","author":"S Hassan","year":"2020","unstructured":"Hassan, S. et al. Liver-on-a-chip models of fatty liver disease. Hepatology 71, 733\u2013740. https:\/\/doi.org\/10.1002\/hep.31106 (2020).","journal-title":"Hepatology"},{"key":"44198_CR22","doi-asserted-by":"publisher","first-page":"152667","DOI":"10.1016\/j.tox.2020.152667","volume":"450","author":"KM Bircsak","year":"2021","unstructured":"Bircsak, K. M. et al. A 3D microfluidic liver model for high throughput compound toxicity screening in the OrganoPlate(R). Toxicology 450, 152667. https:\/\/doi.org\/10.1016\/j.tox.2020.152667 (2021).","journal-title":"Toxicology"},{"key":"44198_CR23","doi-asserted-by":"publisher","first-page":"120904","DOI":"10.1016\/j.biomaterials.2021.120904","volume":"275","author":"Y Teng","year":"2021","unstructured":"Teng, Y., Zhao, Z., Tasnim, F., Huang, X. & Yu, H. A scalable and sensitive steatosis chip with long-term perfusion of in situ differentiated HepaRG organoids. Biomaterials 275, 120904. https:\/\/doi.org\/10.1016\/j.biomaterials.2021.120904 (2021).","journal-title":"Biomaterials"},{"key":"44198_CR24","doi-asserted-by":"publisher","first-page":"034113","DOI":"10.1063\/1.4922863","volume":"9","author":"M Jang","year":"2015","unstructured":"Jang, M., Neuzil, P., Volk, T., Manz, A. & Kleber, A. On-chip three-dimensional cell culture in phaseguides improves hepatocyte functions in vitro. Biomicrofluidics 9, 034113. https:\/\/doi.org\/10.1063\/1.4922863 (2015).","journal-title":"Biomicrofluidics"},{"key":"44198_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s10544-018-0300-x","volume":"20","author":"M Jang","year":"2018","unstructured":"Jang, M., Manz, A., Volk, T. & Kleber, A. Study of melatonin-mediated effects on various hepatic inflammatory responses stimulated by IL-6 in a new HepG2-on-a-chip platform. Biomed. Microdevices 20, 54. https:\/\/doi.org\/10.1007\/s10544-018-0300-x (2018).","journal-title":"Biomed. Microdevices"},{"key":"44198_CR26","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.tiv.2010.02.015","volume":"24","author":"SF Lan","year":"2010","unstructured":"Lan, S. F., Safiejko-Mroczka, B. & Starly, B. Long-term cultivation of HepG2 liver cells encapsulated in alginate hydrogels: A study of cell viability, morphology and drug metabolism. Toxicol. In Vitro 24, 1314\u20131323. https:\/\/doi.org\/10.1016\/j.tiv.2010.02.015 (2010).","journal-title":"Toxicol. In Vitro"},{"key":"44198_CR27","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1039\/c4lc00071d","volume":"14","author":"M Hegde","year":"2014","unstructured":"Hegde, M. et al. Dynamic interplay of flow and collagen stabilizes primary hepatocytes culture in a microfluidic platform. Lab Chip 14, 2033\u20132039. https:\/\/doi.org\/10.1039\/c4lc00071d (2014).","journal-title":"Lab Chip"},{"key":"44198_CR28","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.3390\/ijms24043232","volume":"24","author":"UMN Cao","year":"2023","unstructured":"Cao, U. M. N. et al. Microfluidic organ-on-a-chip: A guide to biomaterial choice and fabrication. Int. J. Mol. Sci. 24, 3232. https:\/\/doi.org\/10.3390\/ijms24043232 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"44198_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.15283\/ijsc.2010.3.2.69","volume":"3","author":"HL Jiang","year":"2010","unstructured":"Jiang, H. L. et al. Roles of spheroid formation of hepatocytes in liver tissue engineering. Int. J. Stem Cells 3, 69\u201373. https:\/\/doi.org\/10.15283\/ijsc.2010.3.2.69 (2010).","journal-title":"Int. J. Stem Cells"},{"key":"44198_CR30","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3390\/mi10100676","volume":"10","author":"J Deng","year":"2019","unstructured":"Deng, J. et al. Engineered liver-on-a-chip platform to mimic liver functions and its biomedical applications: A review. Micromach. (Basel) 10, 676. https:\/\/doi.org\/10.3390\/mi10100676 (2019).","journal-title":"Micromach. (Basel)"},{"key":"44198_CR31","doi-asserted-by":"publisher","first-page":"e13532","DOI":"10.14814\/phy2.13532","volume":"5","author":"PJ Gunn","year":"2017","unstructured":"Gunn, P. J., Green, C. J., Pramfalk, C. & Hodson, L. In vitro cellular models of human hepatic fatty acid metabolism: differences between Huh7 and HepG2 cell lines in human and fetal bovine culturing serum. Physiol. Rep. 5, e13532. https:\/\/doi.org\/10.14814\/phy2.13532 (2017).","journal-title":"Physiol. Rep."},{"key":"44198_CR32","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.3390\/cells9122557","volume":"9","author":"M Stampar","year":"2020","unstructured":"Stampar, M., Breznik, B., Filipic, M. & Zegura, B. Characterization of in vitro 3D cell model developed from human hepatocellular carcinoma (HepG2) cell line. Cells 9, 2557. https:\/\/doi.org\/10.3390\/cells9122557 (2020).","journal-title":"Cells"},{"key":"44198_CR33","doi-asserted-by":"publisher","first-page":"e0166913","DOI":"10.1371\/journal.pone.0166913","volume":"11","author":"MH Seo","year":"2016","unstructured":"Seo, M. H. et al. Exendin-4 inhibits hepatic lipogenesis by increasing beta-catenin signaling. PLoS One 11, e0166913. https:\/\/doi.org\/10.1371\/journal.pone.0166913 (2016).","journal-title":"PLoS One"},{"key":"44198_CR34","doi-asserted-by":"publisher","first-page":"7514802","DOI":"10.1155\/2019\/7514802","volume":"2019","author":"Q Xiao","year":"2019","unstructured":"Xiao, Q. et al. Ginsenoside Rg1 ameliorates palmitic acid-induced hepatic steatosis and inflammation in HepG2 cells via the AMPK\/NF-kappaB pathway. Int. J. Endocrinol. 2019, 7514802. https:\/\/doi.org\/10.1155\/2019\/7514802 (2019).","journal-title":"Int. J. Endocrinol."},{"key":"44198_CR35","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/hep.21752","volume":"46","author":"S Joshi-Barve","year":"2007","unstructured":"Joshi-Barve, S. et al. Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology 46, 823\u2013830. https:\/\/doi.org\/10.1002\/hep.21752 (2007).","journal-title":"Hepatology"},{"key":"44198_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12986-020-0434-8","volume":"17","author":"X Zeng","year":"2020","unstructured":"Zeng, X. et al. Oleic acid ameliorates palmitic acid induced hepatocellular lipotoxicity by inhibition of ER stress and pyroptosis. Nutr. Metab. (Lond) 17, 11. https:\/\/doi.org\/10.1186\/s12986-020-0434-8 (2020).","journal-title":"Nutr. Metab. (Lond)"},{"key":"44198_CR37","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1159\/000447866","volume":"39","author":"AM Hetherington","year":"2016","unstructured":"Hetherington, A. M. et al. Differential lipotoxic effects of palmitate and oleate in activated human hepatic stellate cells and epithelial hepatoma cells. Cell Physiol. Biochem. 39, 1648\u20131662. https:\/\/doi.org\/10.1159\/000447866 (2016).","journal-title":"Cell Physiol. Biochem."},{"key":"44198_CR38","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/j.1440-1746.2008.05733.x","volume":"24","author":"M Ricchi","year":"2009","unstructured":"Ricchi, M. et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J. Gastroenterol. Hepatol. 24, 830\u2013840. https:\/\/doi.org\/10.1111\/j.1440-1746.2008.05733.x (2009).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"44198_CR39","doi-asserted-by":"publisher","first-page":"704112","DOI":"10.3389\/fphar.2021.704112","volume":"12","author":"WR Guo","year":"2021","unstructured":"Guo, W. R. et al. Metformin alleviates steatohepatitis in diet-induced obese mice in a SIRT1-dependent way. Front. Pharmacol. 12, 704112. https:\/\/doi.org\/10.3389\/fphar.2021.704112 (2021).","journal-title":"Front. Pharmacol."},{"key":"44198_CR40","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s12328-021-01491-7","volume":"14","author":"A Malik","year":"2021","unstructured":"Malik, A., Nadeem, M. & Malik, M. I. Efficacy of elafibranor in patients with liver abnormalities especially non-alcoholic steatohepatitis: A systematic review and meta-analysis. Clin. J. Gastroenterol. 14, 1579\u20131586. https:\/\/doi.org\/10.1007\/s12328-021-01491-7 (2021).","journal-title":"Clin. J. Gastroenterol."},{"key":"44198_CR41","doi-asserted-by":"publisher","first-page":"9030","DOI":"10.1038\/s41598-017-09702-3","volume":"7","author":"PJ Hsiao","year":"2017","unstructured":"Hsiao, P. J. et al. Pioglitazone enhances cytosolic lipolysis, beta-oxidation and autophagy to ameliorate hepatic steatosis. Sci. Rep. 7, 9030. https:\/\/doi.org\/10.1038\/s41598-017-09702-3 (2017).","journal-title":"Sci. Rep."},{"key":"44198_CR42","doi-asserted-by":"publisher","first-page":"538183","DOI":"10.1155\/2014\/538183","volume":"2014","author":"J Peng","year":"2014","unstructured":"Peng, J. et al. Effects and potential mechanisms of pioglitazone on lipid metabolism in obese diabetic KKAy mice. PPAR Res. 2014, 538183. https:\/\/doi.org\/10.1155\/2014\/538183 (2014).","journal-title":"PPAR Res."},{"key":"44198_CR43","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-22-0155","author":"SM Lee","year":"2023","unstructured":"Lee, S. M., Muratalla, J., Sierra-Cruz, M. & Cordoba-Chacon, J. Role of hepatic peroxisome proliferator-activated receptor gamma in non-alcoholic fatty liver disease. J. Endocrinol. https:\/\/doi.org\/10.1530\/JOE-22-0155 (2023).","journal-title":"J. Endocrinol."},{"key":"44198_CR44","doi-asserted-by":"publisher","first-page":"5170402","DOI":"10.1155\/2016\/5170402","volume":"2016","author":"N Magee","year":"2016","unstructured":"Magee, N., Zou, A. & Zhang, Y. Pathogenesis of nonalcoholic steatohepatitis: Interactions between liver parenchymal and nonparenchymal cells. Biomed. Res. Int. 2016, 5170402. https:\/\/doi.org\/10.1155\/2016\/5170402 (2016).","journal-title":"Biomed. Res. Int."},{"key":"44198_CR45","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jhep.2022.06.022","volume":"78","author":"SH Saxton","year":"2023","unstructured":"Saxton, S. H. & Stevens, K. R. 2D and 3D liver models. J. Hepatol. 78, 873\u2013875. https:\/\/doi.org\/10.1016\/j.jhep.2022.06.022 (2023).","journal-title":"J. Hepatol."},{"key":"44198_CR46","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1002\/jps.23466","volume":"102","author":"A Legendre","year":"2013","unstructured":"Legendre, A. et al. Metabolic characterization of primary rat hepatocytes cultivated in parallel microfluidic biochips. J. Pharm. Sci. 102, 3264\u20133276. https:\/\/doi.org\/10.1002\/jps.23466 (2013).","journal-title":"J. Pharm. Sci."},{"key":"44198_CR47","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1039\/b809117j","volume":"9","author":"B Ma","year":"2009","unstructured":"Ma, B., Zhang, G., Qin, J. & Lin, B. Characterization of drug metabolites and cytotoxicity assay simultaneously using an integrated microfluidic device. Lab. Chip 9, 232\u2013238. https:\/\/doi.org\/10.1039\/b809117j (2009).","journal-title":"Lab. Chip"},{"key":"44198_CR48","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","volume":"68","author":"M Eslam","year":"2018","unstructured":"Eslam, M., Valenti, L. & Romeo, S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J. Hepatol. 68, 268\u2013279. https:\/\/doi.org\/10.1016\/j.jhep.2017.09.003 (2018).","journal-title":"J. Hepatol."},{"key":"44198_CR49","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1111\/jcmm.14839","volume":"24","author":"S Yuan","year":"2020","unstructured":"Yuan, S. et al. PNPLA3 I148M mediates the regulatory effect of NF-kB on inflammation in PA-treated HepG2 cells. J. Cell Mol. Med. 24, 1541\u20131552. https:\/\/doi.org\/10.1111\/jcmm.14839 (2020).","journal-title":"J. Cell Mol. Med."},{"key":"44198_CR50","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fnut.2020.00039","volume":"7","author":"L Pickel","year":"2020","unstructured":"Pickel, L. & Sung, H. K. Feeding rhythms and the circadian regulation of metabolism. Front. Nutr. 7, 39. https:\/\/doi.org\/10.3389\/fnut.2020.00039 (2020).","journal-title":"Front. Nutr."},{"key":"44198_CR51","doi-asserted-by":"publisher","first-page":"e0159729","DOI":"10.1371\/journal.pone.0159729","volume":"11","author":"M Gori","year":"2016","unstructured":"Gori, M. et al. Investigating nonalcoholic fatty liver disease in a liver-on-a-chip microfluidic device. PLoS One 11, e0159729. https:\/\/doi.org\/10.1371\/journal.pone.0159729 (2016).","journal-title":"PLoS One"},{"key":"44198_CR52","first-page":"95","volume":"2","author":"W Cui","year":"2010","unstructured":"Cui, W., Chen, S. L. & Hu, K. Q. Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells. Am. J. Transl. Res. 2, 95\u2013104 (2010).","journal-title":"Am. J. Transl. Res."},{"key":"44198_CR53","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1053\/j.gastro.2018.06.031","volume":"155","author":"G Musso","year":"2018","unstructured":"Musso, G., Cassader, M., Paschetta, E. & Gambino, R. Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis. Gastroenterology 155, 282\u2013302. https:\/\/doi.org\/10.1053\/j.gastro.2018.06.031 (2018).","journal-title":"Gastroenterology"},{"key":"44198_CR54","doi-asserted-by":"publisher","first-page":"814496","DOI":"10.3389\/fmed.2021.814496","volume":"8","author":"C Liedtke","year":"2021","unstructured":"Liedtke, C. et al. Liver fibrosis-from mechanisms of injury to modulation of disease. Front Med (Lausanne) 8, 814496. https:\/\/doi.org\/10.3389\/fmed.2021.814496 (2021).","journal-title":"Front Med (Lausanne)"},{"key":"44198_CR55","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","volume":"150","author":"V Ratziu","year":"2016","unstructured":"Ratziu, V. et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150, 1147\u20131159. https:\/\/doi.org\/10.1053\/j.gastro.2016.01.038 (2016).","journal-title":"Gastroenterology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44198-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44198-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44198-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:23:17Z","timestamp":1700266997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44198-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["44198"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-44198-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]},"assertion":[{"value":"9 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17019"}}